JP2022545196A5 - - Google Patents

Info

Publication number
JP2022545196A5
JP2022545196A5 JP2022509647A JP2022509647A JP2022545196A5 JP 2022545196 A5 JP2022545196 A5 JP 2022545196A5 JP 2022509647 A JP2022509647 A JP 2022509647A JP 2022509647 A JP2022509647 A JP 2022509647A JP 2022545196 A5 JP2022545196 A5 JP 2022545196A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
seq
fragment
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022509647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545196A (ja
Filing date
Publication date
Priority claimed from GBGB1911799.3A external-priority patent/GB201911799D0/en
Priority claimed from GBGB2010760.3A external-priority patent/GB202010760D0/en
Application filed filed Critical
Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en
Publication of JP2022545196A publication Critical patent/JP2022545196A/ja
Publication of JP2022545196A5 publication Critical patent/JP2022545196A5/ja
Priority to JP2025113769A priority Critical patent/JP2025160218A/ja
Pending legal-status Critical Current

Links

JP2022509647A 2019-08-16 2020-08-14 抗tcrデルタ可変1抗体の治療的使用 Pending JP2022545196A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025113769A JP2025160218A (ja) 2019-08-16 2025-07-04 抗tcrデルタ可変1抗体の治療的使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1911799.3 2019-08-16
GBGB1911799.3A GB201911799D0 (en) 2019-08-16 2019-08-16 Novel Antibodies
GBGB2010760.3A GB202010760D0 (en) 2020-07-13 2020-07-13 Novel antibodies
GB2010760.3 2020-07-13
PCT/GB2020/051959 WO2021032963A1 (en) 2019-08-16 2020-08-14 Therapeutic uses of anti-tcr delta variable 1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025113769A Division JP2025160218A (ja) 2019-08-16 2025-07-04 抗tcrデルタ可変1抗体の治療的使用

Publications (2)

Publication Number Publication Date
JP2022545196A JP2022545196A (ja) 2022-10-26
JP2022545196A5 true JP2022545196A5 (enExample) 2023-08-21

Family

ID=72148174

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022509647A Pending JP2022545196A (ja) 2019-08-16 2020-08-14 抗tcrデルタ可変1抗体の治療的使用
JP2022509648A Pending JP2022544683A (ja) 2019-08-16 2020-08-14 新規な抗tcrデルタ可変1抗体
JP2025113769A Pending JP2025160218A (ja) 2019-08-16 2025-07-04 抗tcrデルタ可変1抗体の治療的使用
JP2025152149A Pending JP2026009903A (ja) 2019-08-16 2025-09-12 新規な抗tcrデルタ可変1抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022509648A Pending JP2022544683A (ja) 2019-08-16 2020-08-14 新規な抗tcrデルタ可変1抗体
JP2025113769A Pending JP2025160218A (ja) 2019-08-16 2025-07-04 抗tcrデルタ可変1抗体の治療的使用
JP2025152149A Pending JP2026009903A (ja) 2019-08-16 2025-09-12 新規な抗tcrデルタ可変1抗体

Country Status (13)

Country Link
US (1) US20220403025A1 (enExample)
EP (2) EP4013505A1 (enExample)
JP (4) JP2022545196A (enExample)
KR (2) KR20220084019A (enExample)
CN (2) CN114222585A (enExample)
AU (4) AU2020332878B2 (enExample)
BR (1) BR112022002837A2 (enExample)
CA (2) CA3145517A1 (enExample)
CL (2) CL2022000368A1 (enExample)
CO (1) CO2022002001A2 (enExample)
IL (1) IL290537A (enExample)
MX (1) MX2022002075A (enExample)
WO (2) WO2021032960A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
WO2019147735A1 (en) 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
CA3127103A1 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用
GB202002581D0 (en) * 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
ES2943063T5 (en) * 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
MX2023009544A (es) 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
KR20230160253A (ko) 2021-02-17 2023-11-23 감마델타 테라퓨틱스 엘티디 항-tcr 델타 가변 1 항체
EP4147716A1 (en) * 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
CA3208653A1 (en) 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
EP4688851A1 (en) 2023-03-27 2026-02-11 LAVA Therapeutics N.V. Nectin-4 binding agents and methods of use
WO2025012118A2 (en) 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN121752599A (zh) * 2023-08-31 2026-03-27 南京传奇生物科技有限公司 抗γδTCR抗体及其用途
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
US20260152558A1 (en) 2024-11-27 2026-06-04 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100591761C (zh) * 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
CN102295702B (zh) * 2011-08-26 2014-01-29 中国科学院微生物研究所 一种针对t细胞受体可变区特异性单抗的制备方法
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
JP6799895B2 (ja) 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. TCRγδ+T細胞の生産方法
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
PE20190115A1 (es) * 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
CN118421557A (zh) 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
US10546518B2 (en) 2017-05-15 2020-01-28 Google Llc Near-eye display with extended effective eyebox via eye tracking
WO2019147735A1 (en) * 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
JP7686571B2 (ja) * 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用

Similar Documents

Publication Publication Date Title
JP2016529882A5 (enExample)
JP2021191763A5 (enExample)
JP2018526981A5 (enExample)
JP2022544683A5 (enExample)
JP2023549537A5 (enExample)
JP2017505121A5 (enExample)
US20210246206A1 (en) Humanized and chimeric monoclonal antibodies to cd47
JP2020529410A5 (enExample)
JP2022533538A5 (enExample)
JP2019536430A5 (enExample)
JP2019515646A5 (enExample)
JP2021524478A5 (enExample)
JP2023071956A5 (enExample)
JP2023515223A5 (enExample)
JP2017533694A5 (enExample)
JP2018510617A5 (enExample)
JP2023548529A5 (enExample)
JP2017507131A5 (enExample)
JPWO2020059847A5 (enExample)
JP2023506750A5 (enExample)
JP2020516309A5 (enExample)
JP2024001073A5 (enExample)
JP2024532489A5 (enExample)
JP2018514193A5 (enExample)
JP2022512646A5 (enExample)